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well known for its antibiotic, anti-inﬂammatory, and antinoci-
ceptive eﬀects.Modulationof synaptic transmission is oneof
the analgesic mechanisms of minocycline. Although it has
been reported that minocyclinemay suppress excitatory glu-
tamatergic synaptic transmission, it remainsunclearwhether
it could aﬀect inhibitory synaptic transmission, which also
plays a key role in modulating pain signaling. To examine
the eﬀect of minocycline on synaptic transmission in rat
spinal substantia gelatinosa (SG) neurons, we recorded
spontaneous inhibitory postsynaptic currents (sIPSCs)
usingwhole-cell patch-clamp recordingat a holdingpotential
of 0 mV. Bath application of minocycline signiﬁcantly
increased the frequency but not the amplitude of sIPSCs in
a reversible and concentration-dependent manner with an
EC50 of 85. The enhancement of inhibitory synaptic trans-
missionproducedbyminocyclinewasnot aﬀectedby theglu-
tamate receptor antagonists CNQX and D-APV or by the
voltage-gated sodium channel blocker tetrodotoxin (TTX).
Moreover, the potency of minocycline for facilitating sIPSC
frequency was the same in both glycinergic and GABAergic
sIPSCs without changing their decay phases. However, the
facilitatory eﬀect of minocycline on sIPSCs was eliminated
inaCa2+-freeKrebssolutionorbyco-administrationwithcal-
cium channel blockers. In summary, our data demonstrate
that baseline inhibitory synaptic transmission in SG neurons
is markedly enhanced by minocycline. This may function to
decrease the excitability of SG neurons, thus leading to a
modulation of nociceptive transmission.  2016 The
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INTRODUCTION
In addition to being well known as a broad-spectrum
antibiotic, minocycline is also a microglial activation
inhibitor that contributes to pain alleviation. The
analgesic eﬀect of minocycline was initially reported in a
rat pain model of L5 spinal nerve transection, in which
intraperitoneal administration of minocycline could
potently attenuate mechanical allodynia and
hyperalgesia (Raghavendra et al., 2003). The antinocicep-
tive role of minocycline has been examined in diverse
pathological states, such as neuropathy (Ledeboer et al.,
2005; Padi and Kulkarni, 2008; Guasti et al., 2009; Ma
et al., 2010), inﬂammation (Hua et al., 2005; Cho et al.,
2006; Kannampalli et al., 2014), cancer (Mao-Ying et al.,
2012), chemotherapy (Di Cesare Mannelli et al., 2014)
and diabetes (Pabreja et al., 2011; Ali et al., 2014;
Syngle et al., 2014). In addition, minocycline not only
improved the analgesic eﬀect of morphine (Chen et al.,
2010; Nazemi et al., 2012; Makuch et al., 2013;
Zychowska et al., 2013) but also attenuated or delayed
morphine tolerance (Mika et al., 2009; Zhang et al.,
2015). These studies suggest that minocycline might be
a promising agent for the clinical treatment of pain when
being used alone or when combined with opioids. The
underlying mechanisms for antinociception of minocycline
have been extensively studied. Currently, most of the stud-
ies are based on the eﬀect of minocycline on the inhibition
of microglial activation and subsequent inﬂammatory cyto-
kine secretion (Garrido-Mesa et al., 2013). However, sev-
eral studies have suggested that minocycline might also
regulate neuronal activity directly. For instance, minocy-
cline inhibited Na+ currents in dorsal root ganglion
(DRG) cells (Kim et al., 2011), suppressed Na+ and
Ca2+ currents in hippocampal neurons (Gonzalez et al.,
2007), and reduced evoked synaptic currents (Cho et al.,
2006) and hyperpolarization-activated cation currents
(Liu et al., 2015) in substantia gelatinosa (SG) neurons.
SG (lamina II of the spinal dorsal horn) plays a crucial
role in regulating nociceptive transmission. It not only
receives nociceptive inputs from myelinated Ad andons.org/licenses/by-nc-nd/4.0/).
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information from local dorsal horn interneurons and the
endogenous descending inhibitory system (Melzack and
Wall, 1965; Wall, 1980). Spinal disinhibition, such as loss
of GABAergic inhibition, is thought to be one of the essen-
tial mechanisms of neuropathic pain (Moore et al., 2002).
Consistent with this, intrathecal administration of GABA
was shown to attenuate neuropathic pain (Eaton et al.,
1999). It has been reported that intrathecal administration
of minocycline could inhibit chemokine CCL2-induced
enhancement of glutamatergic excitatory postsynaptic
currents (EPSCs) in SG neurons (Huang et al., 2014).
To date, little is known about the eﬀect of minocycline on
spontaneous inhibitory postsynaptic currents (sIPSCs).
In this study, we examined the eﬀects and the
underlying cellular mechanisms of minocycline on
sIPSCs and miniature IPSCs (mIPSCs) in rat spinal SG
neurons. We found that minocycline largely enhances the
frequency, but not the amplitude, of inhibitory
postsynaptic currents (IPSCs), suggesting that
presynaptic mechanisms contribute to the eﬀects of
minocycline with the involvement of voltage-activated
calcium channels.EXPERIMENTAL PROCEDURES
All animal experimental protocols were approved by the
Animal Ethics Committee of Nanchang University. We
aimed to minimize the suﬀering of the animals and to
reduce the number of rats studied.Slice preparation
Parasagittal spinal cord slices were prepared as in
previous studies (Lu et al., 2013; Liu et al., 2015). Brieﬂy,
male Sprague–Dawley rats (3–5 weeks old) were deeply
anesthetized with urethan (1.5 g/kg, i.p.) and were then
transcardially perfused with ice-cold carbogenated (95%
O2 and 5% CO2) dissection solution containing (in mM)
240 sucrose, 2.5 KCl, 3.5 MgCl2, 0.5 CaCl2, 1.25 NaH2-
PO4, 0.4 ascorbic acid, 2 pyruvate, and 25 NaHCO3.
The lumbosacral section was quickly removed and
immersed in the dissection solution. After extraction, the
animals were sacriﬁced by exsanguination while still under
anesthesia. The pia-arachnoid membrane was removed
after cutting all ventral and dorsal roots. The spinal section
was then mounted on a vibratome (VT1000S; Leica) cut-
ting stage. Parasagittal slices (300-lm-thick) were cut
and placed in an incubator ﬁlled with normal carbogenated
Krebs solution for at least 30 min at 32 C. The normal
Krebs solution contained (in mM) 117 NaCl, 3.6 KCl, 2.5
CaCl2, 1.2 MgCl2, 1.2 NaH2PO4, 25 NaHCO3, 11 D-
glucose, 0.4 ascorbic acid, and 2 pyruvate.Patch-clamp recordings
Whole-cell voltage-clamp recordings in SG neurons were
operated basically as described previously (Liu et al.,
2008, 2015). In brief, one spinal cord slice was moved
to the recording chamber and continuously perfused with
Krebs solution at room temperature at a perfusing rate of
2–4 ml/min. Recording electrodes were pulled fromborosilicate glass (1.5 mm, 1.12 mm ID; World Precision
Instruments) with a micropipette puller (P-97; Sutter
Instrument). Typical resistance of the pipette was 3–
5 MO when ﬁlled with intracellular solution. The holding
potential (VH) for recording GABAergic and/or glycinergic
IPSCs was 0 mV (at which voltage glutamate-mediated
EPSCs are negligible). The intracellular solution used to
record IPSCs contained the following (in mM): 92
CsMeSO4, 43 CsCl, 10 phosphocreatine, 0.5 EGTA, 10
HEPES, 4 Mg-ATP, 0.3 Li-GTP, and 5 tetraethylammo-
nium (TEA)-Cl (pH = 7.2, adjusted with CsOH,
300 mOsm). Potassium-channel blockers (Cs+ and
TEA) were used to steadily hold the membrane potentials
at 0 mV. In some experiments, a nominally Ca2+-free
Krebs solution was used with the following (in mM):
113.1 NaCl, 3.6 KCl, 5 MgCl2, 1.2 NaH2PO4, 11 glucose,
and 25 NaHCO3 (tonicity was adjusted by lowering the
concentration of Na+). Liquid junction potential was not
corrected in this study. Signals were ampliﬁed with an
EPC-10 ampliﬁer and Patch master software (HEKA)
and were stored on a computer for further analysis. Series
resistances were generally 20–30 MO and were moni-
tored during the recording. The data were not used if
the series resistance change was >20%.
Application of drugs
All drugs were bath applied by gravity through three-way
stopcocks. The time necessary for the solution to ﬂow
from the stopcocks to the slice was approximately 15 s.
The drugs used were minocycline, 100 lM doxycycline
(a second-generation tetracycline), 100 lM DL-ﬂuorocitric
acid barium salt (a selective astrocyte inhibitor), 10 lM
CNQX (an AMPA/kainate receptor antagonist), 50 lM
APV (an NMDA receptor antagonist), 0.5–1 lM
tetrodotoxin (TTX, a voltage-gated sodium channel
blocker), 10–40 lM bicuculline methiodide (a GABAA
receptor antagonist), 1–2 lM strychnine (a glycine
receptor antagonist), 100 lM NiCl2 (a low voltage-
activated calcium channel blocker), and 100 lM CdCl2 (a
high voltage-activated calcium channel blocker).
Minocycline and doxycycline were freshly dissolved in
Krebs solution at the ﬁnal concentration before
perfusion. A stock of ﬂuorocitrate was prepared from DL-
ﬂuorocitric acid barium salt as previously described
(Wenker et al., 2010). A stock of CNQX was ﬁrst dissolved
in dimethyl sulfoxide, and the other drugs were prepared in
distilled water at 1000 times the concentrations to be used
and stored at -20 C as in our previous study (Liu et al.,
2015). The drugs were diluted to the ﬁnal concentration
in Krebs solution just before use. Doxycycline, CNQX,
APV, and TTX were obtained from Tocris Bioscience
(Bristol, UK). All other chemicals were purchased from
Sigma–Aldrich (St. Louis, MO). The determination of the
doses for minocycline was based on a previous study in
which 100 lM minocycline markedly reduced the fre-
quency and amplitude of spontaneous EPSCs (sEPSCs)
in hippocampal neurons (Gonzalez et al., 2007).
Statistical analysis
The frequencies and amplitudes of IPSCs were analyzed
with Mini Analysis (version 6.0.3; Synaptosoft, Decatur,
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5.0 (GraphPad Software, USA). SPSS version 17.0 was
used for all the statistical analysis, except where noted.
The normal distribution of data was tested with the
Shapiro–Wilk test. Homogeneity of variance was
assessed by Levene test. The data were expressed as
mean ± SEM; n indicates the number of neurons
Comparisons between two dependent groups were
conducted with Two-sample paired Student’s t-tests. A
one-way ANOVA followed by post hoc of Bonferroni
correction was used for the comparisons of more than
two groups. Kolmogorov–Smirnov test (KS test) was
used for the comparison of cumulative probabilities of
frequency and amplitude. The KS test was run online at
http://www.physics.csbsju.edu/stats/KS-test.n.plot_form.
html (Lowe and Bailey, 2015). A diﬀerence was considered
to be signiﬁcant at P< 0.05.
RESULTS
Minocycline enhances inhibitory synaptic
transmission in SG neurons
To investigate the eﬀect of minocycline on inhibitory
transmission, whole-cell voltage-clamp recordings from
SG neurons were made under control conditions and
after bath application of minocycline (100 lM).
Minocycline treatment did not alter sIPSC amplitude, but
gradually increased sIPSC frequency (Fig. 1A). The
frequency and amplitude of sIPSCs under the action of
minocycline were 220 ± 10% (P< 0.05) and 105 ± 3%
(P> 0.05) of the control (2.5 ± 0.3 Hz and 24.8 ± 2.0
pA), respectively (Fig. 1D). This enhancement of sIPSC
frequency by minocycline conﬁrmed that it could increase
the inhibitory neurotransmitter, i.e., GABA/glycine release
from the presynaptic terminal. However, minocycline has
been recognized as playing two mainly independent
roles: it is a microglial inhibitor as well as a second-
generation tetracycline. Since microglia is an upstream
partner of astrocytes in response to stimuli (Pascual
et al., 2012), we next examined whether astrocyte activa-
tion will aﬀect sIPSCs. Unlike minocycline, ﬂuorocitrate
itself did not aﬀect the frequency and amplitude of sIPSCs
(Fig. 1B, D). When the slices were pretreated with ﬂuoroc-
itrate, we observed no diﬀerences in sIPSC frequency and
amplitudewith the bath application ofminocycline (data not
shown). The ﬁnding that ﬂuorocitrate did not aﬀect the
minocycline responsessuggests that the increase in sIPSC
frequency by the latter drug might not be due to the role of
astrocyte activation in the spinal dorsal horn. To further
examine the possiblemolecular target, we applied a substi-
tute second-generation tetracycline, doxycycline, to SG
neurons. Similar to the eﬀect of ﬂuorocitrate on sIPSCs,
doxycycline also did not aﬀect sIPSCs (Fig. 1C). Thus,
the above results raise the possibility that minocycline
may have some unknown action that aﬀects neurons, and
this possibility needs to be further investigated.
Minocycline enhances sIPSCs in a concentration-
dependent manner
To examine whether the facilitatory eﬀect of minocycline
on sIPSCs is concentration dependent, we appliedminocycline in a concentration range from 1 to 300 lM
to spinal slices. The frequency of sIPSCs was not
altered at 1 lM, but increased to 284 ± 27% of the
control at 300 lM (n= 10, P< 0.05) (Fig. 2A, B).
However, minocycline did not increase the amplitude of
sIPSCs even at 300 lM (113 ± 6% of control,
P> 0.05). This indicates that minocycline increases the
probability of inhibitory neurotransmitter release from the
presynaptic terminal into a synapse without a
postsynaptic eﬀect. In this study, concentrations of
minocycline higher than 300 lM were not used because
the drug could not be completely dissolved in Krebs
solution at room temperature at a concentration of
>300 lM. Taken together, our ﬁndings indicate that
minocycline increases the frequency of sIPSCs in a
concentration-dependent manner (EC50 of 85 lM)
without changing their amplitude, suggesting a
presynaptic mechanism that contributes to the eﬀect of
minocycline (Fig. 2C).Minocycline increases both glycinergic and
GABAergic sIPSC frequencies
In spinal SG neurons, both glycinergic and GABAergic
sIPSCs were recorded as previously described (Yang
et al., 2004; Liu et al., 2008). To determine whether there
was a diﬀerence in the eﬀects of minocycline on glyciner-
gic and GABAergic sIPSCs, we pretreated the slices with
GABAA or glycine receptor antagonists to distinguish
putative glycinergic and GABAergic sIPSCs (Fig. 3A, E).
As illustrated in Fig. 3C and G, minocycline increased
the frequencies of glycinergic and GABAergic sIPSCs to
219 ± 7% (n= 8, P< 0.05) of the control (1.7
± 0.3 Hz) and 214 ± 9% (n= 9, P< 0.05) of the control
(1.6 ± 0.2 Hz), respectively. Cumulative distribution
curves showed that minocycline shortened the inter-
event interval of glycinergic and GABAergic sIPSCs
(P< 0.05; KS test) but did not aﬀect the amplitude
(P> 0.05; KS test) (Fig. 3D, H). Furthermore, the decay
phases of glycinergic and GABAergic sIPSCs were not
altered by minocycline (Fig. 3B, F). These data suggested
that minocycline aﬀects both glycinergic and GABAergic
presynaptic terminals.Inhibitory transmission enhancement produced by
minocycline is independent of neuronal activity
To test the possibility that glutamatergic synaptic
transmission aﬀects the excitability of SG neurons and
may be involved in the facilitation of minocycline on
sIPSCs, we added the glutamate receptor blockers
CNQX and APV into the bath solution before
minocycline treatment. As shown in Fig. 4A, C, E, the
enhancement eﬀect of minocycline on sIPSCs was not
abolished by glutamate receptor antagonists. The
frequency increased to 217 ± 4% (n= 5, P< 0.05) of
the control (2.0 ± 0.1 Hz). Similarly, minocycline had no
eﬀect on the amplitude of sIPSCs in the presence of
CNQX and APV (Fig. 4C, E and Table 1).
To further examine whether neuronal activity
contributes to the increase in sIPSC frequency
produced by minocycline, we next tested whether TTX
Fig. 1. The enhancement of sIPSCs caused by minocycline in SG neurons cannot be mimicked by ﬂuorocitrate and doxycycline. (A):
Representative continuous chart recording shows an increase in sIPSC frequency resulting from bath application of minocycline (3 min). In this and
subsequent ﬁgures, a bar on the top of the recording indicates the perfusion period. Lower consecutive traces, which are shown in an expanded time
scale before (left) and under (right) the action of minocycline, correspond to a period indicated by a bar shown below the chart recording. (B, C):
Representative continuous chart recordings obtained from bath application of ﬂuorocitrate (3 min, B) or doxycycline (3 min, C). (D): Summary of the
eﬀects on frequency (left) and amplitude (right) of sIPSCs elicited by minocycline (n= 17), ﬂuorocitrate (n= 15) and doxycycline (n= 12), which
were normalized to the control. In this and the following ﬁgures, error bars indicate SEM. * indicates signiﬁcantly diﬀerent from the control
(P< 0.05). VH = 0 mV.
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control conditions, minocycline signiﬁcantly increased the
frequency of mIPSCs (sIPSCs in the presence of TTX) to
236 ± 9% (n= 16, P< 0.05) of the control (2.2
± 0.2 Hz) but not the amplitude (105 ± 3% of the
control: 20.2 ± 1.2 pA) (Fig. 4D, E and Table 1). This
increase was consistent with the results of cumulativedistributions of the inter-event interval and the amplitude
of sIPSCs in the absence and presence of minocycline.
As illustrated in Fig. 4D, minocycline shifted the
cumulative frequency distribution of mIPSC frequency to
the left (P< 0.05; KS test) but did not change mIPSC
amplitude (P> 0.05; KS test). Meanwhile, the
facilitatory eﬀect of minocycline on mIPSCs is not
Fig. 2. Minocycline increases the frequency of sIPSCs in SG neurons in a concentration-dependent manner. (A): Chart recordings of sIPSCs
obtained from the same neuron in the absence and presence of minocycline at concentrations of 10, 40, and 100 lM, respectively. (B): Summarized
data show the percentage change in sIPSC frequency and amplitude under the diﬀerent concentrations of minocycline, relative to the control. (C):
Relative frequency elicited by minocycline at various concentrations, plotted against the logarithm of minocycline concentration. The value in the
parentheses is the number of cells examined. The concentration–response curve was ﬁtted using the Hill equation: y= Imax/(1 + EC50/x), where x
is minocycline concentration in lM (EC50 = 85 lM; Hill coeﬃcient = 2.4).
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These results clearly demonstrate that minocycline-
induced facilitation is not mediated by neuronal activity,
but by direct action on the inhibitory presynaptic terminal.Inhibitory transmission enhancement produced by
minocycline is due to presynaptic Ca2+ inﬂux
To test whether presynaptic Ca2+ inﬂux was involved in
the increase of IPSC frequency by minocycline, we ﬁrst
examined the eﬀect of minocycline (100 lM) on sIPSCs
in the presence of a nominally Ca2+-free Krebs solution.
Consistent with previous ﬁndings (Yang et al., 2004; Liu
et al., 2008), we found that the lack of extracellular
Ca2+ itself reduced the frequency and amplitude of
sIPSCs to 17 ± 2% (n= 11, P< 0.05) and 74 ± 3%
(n= 11, P< 0.05) of the control (5.3 ± 0.4 Hz and
25.0 ± 1.3 pA), respectively (Fig. 5A). Under the same
conditions, minocycline did not aﬀect the frequency and
amplitude of sIPSCs, which were 100 ± 3% (n= 11,
P> 0.05) and 102 ± 2% (n= 11, P> 0.05) of the con-
trol (0.9 ± 0.1 Hz and 18.2 ± 0.7 pA), respectively
(Fig. 5D and Table 1). This suggests that extracellular
Ca2+ is necessary for the minocycline-induced sIPSC
frequency increase.
A variety of diﬀerent types of voltage-gated calcium
channels, such as N-type, R-type, and T-type, are
expressed in the spinal dorsal horn, which is associated
with pain signaling (Bourinet et al., 2014). Because it is
not possible to test the eﬀects of all of the calcium
blockers in the present study, we selected a lowvoltage-activated (LVA) calcium channel blocker, NiCl2,
and a high voltage-activated (HVA) calcium channel
blocker, CdCl2, to assess whether presynaptic voltage-
gated calcium channels are involved in the response of
minocycline. NiCl2 (100 lM) alone decreased the fre-
quency and amplitude of sIPSCs to 60 ± 3% (n= 9;
P< 0.05) and 84 ± 4% (n= 9; P< 0.05) of the control
(2.6 ± 0.3 Hz and 37.7 ± 4.6 pA), respectively. Pretreat-
ment with NiCl2 for 4 min diminished the enhancement of
inhibitory synaptic transmission by minocycline (Fig. 5B).
The frequency and amplitude of sIPSCs were 97 ± 1%
(n= 9, P> 0.05) and 101 ± 2% (n= 9, P> 0.05) of
the control (1.6 ± 0.2 Hz and 31.9 ± 4.8 pA), respec-
tively. Moreover, the HVA calcium channel blocker CdCl2
had an eﬀect similar to NiCl2 (Fig. 5C). CdCl2 decreased
the frequency and amplitude of sIPSCs to 25 ± 4%
(n= 11; P< 0.05) and 64 ± 5% (n= 11; P< 0.05) of
the control (2.7 ± 0.2 Hz and 34.3 ± 2.9 pA), respec-
tively. The frequency and amplitude of sIPSCs pretreated
with CdCl2 in the presence of minocycline were 105 ± 3%
(n= 11, P> 0.05) and 101 ± 2% (n= 11, P> 0.05) of
the control (0.7 ± 0.2 Hz and 21.0 ± 1.1 pA), respec-
tively. These ﬁndings demonstrate that presynaptic cal-
cium channels inhibit the facilitation of minocycline on
GABA/glycine release.DISCUSSION
This study reveals a novel cellular mechanism by which
minocycline decreases the excitability of SG neurons
Fig. 3. Eﬀects of minocycline on glycinergic and GABAergic sIPSCs in SG neurons. (A): Representative recordings of glycinergic sIPSCs in the
absence and presence of minocycline. (B): Superimposed average traces of 35 and 78 glycinergic sIPSCs measured for 30 s in the control (black
line) and under the inﬂuence of minocycline (gray line). (C): Summary bar graphs illustrating the eﬀect of minocycline on the average frequency and
amplitude of glycinergic sIPSCs. (D): Minocycline shifted the frequency distribution of glycinergic sIPSCs to a shorter inter-event interval (P< 0.05;
KS test) but did not aﬀect the amplitude distribution (P> 0.05; KS test). (E): Representative recordings of GABAergic sIPSCs in the absence and
presence of minocycline. (F): Superimposed average traces of 53 and 105 GABAergic sIPSCs measured for 30 s in the control (black line) and
under the inﬂuence of minocycline (gray line). (G): Summary bar graphs illustrating the eﬀect of minocycline on the average frequency and
amplitude of GABAergic sIPSCs. (H): Minocycline shifted the frequency distribution of GABAergic sIPSCs to a shorter inter-event interval
(P< 0.05; KS test) but did not aﬀect the amplitude distribution (P> 0.05; KS test).
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inhibitory neurotransmitter release.
Minocycline, a semisynthetic tetracycline, is well
known for its functions, such as neuroprotection or
antihypernociception, that have been identiﬁed in the
last decade, and it typically acts by blocking microglial
activation and reducing proinﬂammatory cytokineproduction (Yong et al., 2004). However, some publica-
tions have demonstrated that minocycline may aﬀect fast
synaptic transmission; therefore, other potential mecha-
nisms should not be ruled out. Moreover, the eﬀect of
minocycline may diﬀer on diﬀerent types of neurons. For
example, minocycline (50 nM) had no eﬀect on basal exci-
tatory synaptic transmission in CA1 (Pascual et al., 2012)
Fig. 4. The enhancement eﬀect of minocycline on sIPSCs is not aﬀected by pretreatment with CNQX, D-APV or TTX. (A): The superfusion of
CNQX and D-APV not abolished the enhancement eﬀect of minocycline on sIPSC. (B): Recordings of mIPSC before and after the application of
minocycline when the slice was pretreated with TTX. (C): Minocycline shifted the frequency distribution of sIPSCs to a shorter inter-event interval
(P< 0.05; KS test) but did not aﬀect the amplitude distribution (P> 0.05; KS test). (D): Minocycline shifted the frequency distribution of mIPSCs to
a shorter inter-event interval (P< 0.05; KS test) but did not aﬀect the amplitude distribution (P> 0.05; KS test). (E): Grouped data show the
percentage change in frequency (left) and amplitude (right) after administration of minocycline alone (n= 17), with CNQX and D-APV (n= 5), or
with TTX (n= 16), relative to the control.
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minocycline may inhibit dorsal root entry zone
stimulation-elicited EPSCs in SG neurons (Cho et al.,
2006) or may decrease sEPSC frequency and amplitude
in hippocampal neurons (Gonzalez et al., 2007). At a con-
centration of 200 lM, minocycline may decrease C-ﬁberevoked ﬁeld potentials in the spinal dorsal horn, indicating
an inhibition of excitatory synaptic transmission (Zhong
et al., 2010). In addition, minocycline at 500 lM abolished
the mustard oil-induced glutamatergic-dependent central
sensitization in medullary dorsal horn nociceptive neurons
(Itoh et al., 2011). The above observations suggest that
Table 1. Frequency and amplitude of IPSCs, relative to control
Condition Percentage of control Control Number of cells
Frequency Amplitude Frequency (Hz) Amplitude (pA)
Krebs solution 220 ± 10* 105 ± 3 2.5 ± 0.3 24.8 ± 2.0 17
+Bicuculline 219 ± 7* 105 ± 4 1.7 ± 0.3 30.4 ± 3.1 8
+Strychnine 214 ± 9* 114 ± 3 1.6 ± 0.2 20.7 ± 1.5 9
+CNQX+ APV 217 ± 4* 107 ± 4 2.0 ± 0.1 29.6 ± 3.7 5
+TTX 236 ± 9* 105 ± 3 2.2 ± 0.2 20.2 ± 1.2 16
Ca2+-free Krebs solution 100 ± 3 102 ± 2 0.9 ± 0.1 18.2 ± 0.7 11
+NiCl2 97 ± 1 101 ± 2 1.6 ± 0.2 31.9 ± 4.8 9
+CdCl2 105 ± 3 101 ± 2 0.7 ± 0.2 21.0 ± 1.1 11
Frequency and amplitude were measured around 3 min after beginning of minocycline (100 lM) superfusion under various conditions. Values are mean ± SEM.
* P< 0.05.
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concentration- and cell-type-dependent manner by
decreasing glutamatergic transmission. In addition to
excitatory input, neurons also receive inhibitory synaptic
transmission. If minocycline could modulate inhibitory
synaptic transmission, then IPSC frequency or amplitude
must be inﬂuenced by minocycline. In the present study,
we focused on inhibitory transmission because disinhibi-
tion of SG neurons is an important mechanism of patho-
logical pain (Todd, 2010). Our study showed that
minocycline increased sIPSC and mIPSC frequency with-
out changing the amplitude. Generally, the increase in
sIPSC or sEPSC frequency enhanced the probability of
neurotransmitter release from the presynaptic terminal.
Thus, the eﬀect of minocycline on SG neurons is mainly
of a presynaptic origin rather than a postsynaptic origin.
The observation that minocycline had no eﬀect on exoge-
nous GABA-induced current further demonstrates this
ﬁnding (Gonzalez et al., 2007). Our previous study found
that minocycline could inhibit hyperpolarization-activated
cyclic nucleotide-gated (HCN) channels in SG neurons
(Liu et al., 2015). Both of these two eﬀects of minocycline
suggest it could be used as an analgesic.
Although microglial activation is usually found from 1
to 3 days after nerve injury (Inoue and Tsuda, 2009), we
cannot absolutely exclude a glia-mediated eﬀect of
minocycline. It has been reported that the activity of astro-
cytes would be triggered by activation of microglia in
pathological pain (Pascual et al., 2012). Moreover, pre-
treatment of brain slices with ﬂuorocitrate (100 lM for
30 min) increased sIPSC duration in ventrobasal nucleus
neurons or decreased sIPSC duration in the thalamic
reticular nucleus neurons (Christian and Huguenard,
2013). Thus, we next investigated whether ﬂuorocitrate
has the same eﬀect as minocycline in sIPSCs of SG neu-
rons. Unexpectedly, neither the frequency nor the ampli-
tude of sIPSCs was aﬀected by ﬂuorocitrate. We also
investigated the response of minocycline to pretreatment
with ﬂuorocitrate. Again, we found that ﬂuorocitrate does
not alter the eﬀect of minocycline. Therefore, it can be
concluded that, at least in the current study, sIPSC
enhancement by minocycline is not due to glial activation.
Like minocycline, doxycycline is also eﬀective at blocking
pathological pain in animal models (Bastos et al., 2007).
This eﬀect is potentially regulated by the same mecha-
nism as the eﬀect of minocycline. In our study, however,doxycycline could not mimic minocycline’s facilitation of
inhibitory transmission. Thus, it is improbable that the
response of minocycline is produced by microglial activa-
tion or by its antibiotic eﬀect.
It is well known that there are many inhibitory axon
terminals, including monoamine- or GABA-containing
descending ﬁbers and inhibitory interneurons in SG
(Todd, 2010). GABA and glycine have been found to be
coreleased in the spinal dorsal horn (Jonas et al., 1998).
Therefore, minocycline should exert the same eﬀect on
glycinergic and GABAergic sIPSCs. Accordingly, we
observed that both strychnine-sensitive, glycine
receptor-mediated sIPSCs and bicuculline-sensitive,
GABAA receptor-mediated sIPSCs are enhanced by
minocycline.
Neurotransmitter release from the presynaptic
terminal is triggered by a Na+ channel-dependent action
potential, a subthreshold depolarizing current spread
from the somatodendritic region, and presynaptic ligand-
gated channel activation. For example, an endogenous
peptide antisecretory factor reduced the frequency of
sIPSCs, but not mIPSCs, in CA1 pyramidal neurons
(Strandberg et al., 2014). Likewise, if an increase in
sIPSC frequency is triggered by a Na+ channel-
dependent action potential, then the Na+ channel blocker
TTX should block the eﬀect of minocycline. In contrast,
the increase in mIPSC frequency induced by minocycline
was not blocked by bath application of TTX. It has been
demonstrated that Na+ channels, which account for
action potential propagation expressed in lamina I/II of
the spinal cord, are entirely TTX-sensitive (Hildebrand
et al., 2011). Therefore, our results together with the pub-
lished literature suggest that a Na+ channel-dependent
action potential is not involved in the eﬀect of minocycline
on inhibitory transmission. It remains unclear whether a
subthreshold depolarizing current spread from the soma-
todendritic region contributes to minocycline response.
We next investigated whether glutamate receptor-
mediated sEPSCs are involved in the increase in GABA
and glycine release. Our data show that the eﬀect of
minocycline under the treatment with CNQX and APV
was the same as with TTX. Therefore, it is possible that
the enhancement of inhibitory neurotransmitter release
is due to presynaptic ligand-gated channel activation.
The spontaneous synaptic neurotransmitter release of
dorsal horn neurons relies critically on presynaptic
Fig. 5. The enhancement of sIPSC frequency produced by minocycline is due to presynaptic calcium inﬂux. (A): Recording of sIPSCs in the
absence and presence of minocycline in a nominally Ca2+-free Krebs solution. (B, C): Recordings of sIPSCs in the absence and presence of
minocycline pretreated with LVA blocker NiCl2 (B) or HVA blocker CdCl2 (C). The minocycline-induced enhancement of inhibitory transmission was
blocked by NiCl2 and CdCl2. (D): Summary data showing sIPSC frequency (left) and amplitude (right) under the inﬂuence of minocycline in normal
Krebs solution (n= 17), Ca2+-free Krebs solution (n= 11), NiCl2 (n= 9) and CdCl2 (n= 11), relative to the control.
H.-Z. Peng et al. / Neuroscience 319 (2016) 183–193 191voltage-gated calcium channels (Bourinet et al., 2014). In
the present study, sIPSC frequency was largely inhibited
in a Ca2+-free Krebs solution, indicating that voltage-
gated calcium channels possibly contribute to this eﬀect.
Based on the voltage dependence of activation, calcium
channels in the spinal dorsal horn can be divided into
two groups: HVA and LVA calcium channels (Bourinetet al., 2014). Given that LVA calcium channels open at
voltages near resting membrane potential, it is possible
that these channels contribute to the response of minocy-
cline. We ﬁrst investigated the eﬀect of the LVA calcium
channel blocker NiCl2 and found that it blocked minocy-
cline’s facilitation of sIPSC frequency. Meanwhile, the
HVA calcium channel blocker CdCl2 also blocked the
192 H.-Z. Peng et al. / Neuroscience 319 (2016) 183–193eﬀect of minocycline. Thus, our results demonstrated that
minocycline enhanced GABA and glycine release for the
activation of presynaptic voltage-gated calcium channels.
The neuronal circuit of SG is composed of complex
synaptic connections and plays an important role in pain
signaling. Disinhibition, i.e., the reduction of GABAergic
and/or glycinergic inhibitory transmission in the spinal
dorsal horn, has been suggested to underlie the
mechanisms of chronic pain (Todd, 2010). In contrast,
drugs, such as norepinephrine (Georgiev et al., 2006)
and serotonin (Abe et al., 2009) that enhance inhibitory
transmission and, therefore, lead to a reduction in neu-
ronal excitability could be used as antinociceptive agents.
Although the facilitatory eﬀect of minocycline on inhibitory
transmission in SG neurons is less pronounced compared
with the eﬀects of norepinephrine or serotonin, as men-
tioned above, minocycline has been shown to be an eﬀec-
tive analgesic in a variety of animal pain models (Garrido-
Mesa et al., 2013). In addition, minocycline displays an
enhanced antinociceptive eﬀect when co-administered
with non-steroidal anti-inﬂammatory drugs, including indo-
methacin or aspirin (Abu-Ghefreh and Masocha, 2010;
Bhatt and Addepalli, 2010; Parvathy and Masocha,
2015). Furthermore, minocycline raised the analgesic
eﬀect of dynorphin (Rojewska et al., 2014), nociceptin
(Popiolek-Barczyk et al., 2014), and tramadol (Mei
et al., 2013). We have recently shown that minocycline
could decrease neuronal excitability by reducing the ﬁring
rates in response to depolarizing current injection in SG
neurons (Liu et al., 2015). In accordance with this report,
we found that minocycline could enhance inhibitory presy-
naptic transmission due to an increased probability of
release from nerve terminals, resulting in the inhibition
of SG neurons.
CONCLUSIONS
Taken together, our results elucidate a novel cellular
mechanism underlying minocycline-induced enhance-
ment of inhibitory synaptic transmission in superﬁcial
spinal dorsal horn neurons. This action of minocycline
may lead to the decreased excitability of SG neurons
and may play a potential role in the modulation of
neuropathic pain.
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